Item 8.01. Other Events
On September 13, 2021, Y-mAbs Therapeutics, Inc., (the "Company") issued a press
release announcing that its partner SciClone Pharmaceuticals (Holdings) Limited
has been granted priority review of the Biologics License Application for
DANYELZA® (naxitamab-gqgk) for the treatment of patients with
relapsed/refractory high-risk neuroblastoma by the Center for Drug Evaluation of
China'sNational Medical Products Administration. A copy of the press release is
attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 8.01 on this Form 8-K, including
Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference into any other filing under the Securities Act
or the Exchange Act, except as expressly set forth by specific reference in such
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press Release, dated September 13, 2021 issued by Y-mAbs
104 Interactive Data File (embedded within the Inline XBRL document).
© Edgar Online, source Glimpses